Screening for PIK3CA, RAS, and RAF mutations in trials with PI3K/AKT/mTOR signaling pathway inhibitors

被引：0
|
作者：
Janku, F.
Tsimberidou, A. M.
Garrido-Laguna, I.
Hong, D. S.
Naing, A. M.
Falchook, G. S.
Fu, S.
Luthra, R. [1 ]
Wang, X. [2 ]
Kurzrock, R.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Mol Diagnost Lab, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)71959-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：83 / 83
页数：1
相关论文
共 50 条
  • [1] PIK3CA Mutations PREDICT RESPONSE TO PI3K/AKT/mTOR INHIBITORS
    不详
    [J]. CANCER DISCOVERY, 2012, 2 (03) : 205 - 205
  • [2] PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
    Janku, Filip
    Tsimberidou, Apostolia M.
    Garrido-Laguna, Ignacio
    Wang, Xuemei
    Luthra, Rajyalakshmi
    Hong, David S.
    Naing, Aung
    Falchook, Gerald S.
    Moroney, John W.
    Piha-Paul, Sarina A.
    Wheler, Jennifer J.
    Moulder, Stacy L.
    Fu, Siqing
    Kurzrock, Razelle
    [J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (03) : 558 - 565
  • [3] Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
    Janku, Filip
    Hong, David S.
    Fu, Siqing
    Piha-Paul, Sarina A.
    Naing, Aung
    Falchook, Gerald S.
    Tsimberidou, Apostolia M.
    Stepanek, Vanda M.
    Moulder, Stacy L.
    Lee, J. Jack
    Luthra, Rajyalakshmi
    Zinner, Ralph G.
    Broaddus, Russell R.
    Wheler, Jennifer J.
    Kurzrock, Razelle
    [J]. CELL REPORTS, 2014, 6 (02): : 377 - 387
  • [4] PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
    Janku, Filip
    Wheler, Jennifer J.
    Westin, Shannon N.
    Moulder, Stacy L.
    Naing, Aung
    Tsimberidou, Apostolia M.
    Fu, Siqing
    Falchook, Gerald S.
    Hong, David S.
    Garrido-Laguna, Ignacio
    Luthra, Rajyalakshmi
    Lee, J. Jack
    Lu, Karen H.
    Kurzrock, Razelle
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) : 777 - 782
  • [5] RAS Signaling in the PI3K/AKT/MTOR Pathway
    Nussinov, Ruth
    Zhang, Mingzhen
    Jang, Hyunbum
    [J]. BIOPHYSICAL JOURNAL, 2020, 118 (03) : 51A - 51A
  • [6] Activation of the PI3K/AKT pathway and PIK3CA mutations in Merkel cell carcinoma
    Hafner, C.
    Houben, R.
    Baeurle, A.
    Landthaler, M.
    Becker, J. C.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2010, 8 (09): : 739 - 739
  • [7] PIK3CA regulates development of diabetes retinopathy through the PI3K/Akt/mTOR pathway
    Guan, Ruijuan
    Kang, Zefeng
    Li, Ling
    Yan, Xin
    Gao, Tianpeng
    [J]. PLOS ONE, 2024, 19 (01):
  • [8] Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies
    Asati, Vivek
    Bharti, Sanjay K.
    Mahapatra, Debarshi Kar
    Asati, Vikas
    Budhwani, Ashok K.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (39) : 6039 - 6054
  • [9] PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
    Janku, Filip
    Wheler, Jennifer J.
    Naing, Aung
    Falchook, Gerald S.
    Hong, David S.
    Stepanek, Vanda M.
    Fu, Siqing
    Piha-Paul, Sarina A.
    Lee, J. Jack
    Luthra, Rajyalakshmi
    Tsimberidou, Apostolia M.
    Kurzrock, Razelle
    [J]. CANCER RESEARCH, 2013, 73 (01) : 276 - 284
  • [10] Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example
    Zheng, Shutao
    He, Shuo
    Liang, Yan
    Tan, Yiyi
    Liu, Qing
    Liu, Tao
    Lu, Xiaomei
    [J]. MOLECULAR BIOMEDICINE, 2024, 5 (01):
12345